Sapient

#Proteindegraders like PROTACs and molecular glues have the potential to significantly expand the druggable space. Effective development of these therapies demands a method that is optimized to broadly screen degrader molecules for target selectivity as well as for deep profiling of chosen degraders across different cell lines, drugs, doses, and time points. Learn how mass spectrometry-based 𝐏𝐫𝐨𝐭𝐞𝐢𝐧 𝐃𝐞𝐠𝐫𝐚𝐝𝐞𝐫 𝐏𝐫𝐨𝐭𝐞𝐨𝐦𝐢𝐜𝐬 enables both: • High throughput cell-based screening of thousands of degrader compounds for a target of interest, and • Deep proteome profiling to comprehensively assay selected protein degraders, including assessment of on-target and off-target effects https://lnkd.in/gBbuXAMU

We are very excited to participate in this symposium and the conversations that are integral to moving #multiomics and #precisionmedicine forward. Check out more highlights of the agenda and how to register to join us! 🔽 https://lnkd.in/g7YszD7b

In what key areas can mass spectrometry-based #proteomics and #metabolomics add insight value for drug development? In a recent interview with PharmaShots, Sapient's Dr. Jonathan Usuka shares examples of how these approaches are being applied across phases, from early discovery including target identification and high throughput drug screening to preclinical translation and in #clinicaltrials. Watch the clip below and access the full video to hear more: https://lnkd.in/gACSMepi

Join this inaugural 𝐯𝐢𝐫𝐭𝐮𝐚𝐥 𝐌𝐮𝐥𝐭𝐢-𝐎𝐦𝐢𝐜𝐬 𝐒𝐲𝐦𝐩𝐨𝐬𝐢𝐮𝐦 on November 12, presented by Oxford Global, to hear how delegates across pharma, biotech, and academia are leveraging #multiomics technologies and techniques to amplify #biomarker discovery and toward the development of precision medicines. From presentations to collaborative panels, the symposium will bring together scientific and technological innovators for focused conversations on multi-omics advancements in drug development, including topics such as: ➡️ Inflammatory Disease Biomarker Development Using Omics Approaches ➡️ Next-Generation Multi-Omics to Amplify Drug Development Insights ➡️ Single Cell Spatial Proteomics & Transcriptomics ➡️ Multimodal Analysis Towards Biomarker Complexity Learn more about Sapient's featured presentation and panel, and secure your spot!: https://lnkd.in/gHFYrBwZ

Multifaceted diseases like #CKD present significant challenges in both diagnosis and management, necessitating a more nuanced approach for effective treatment. Existing classification systems used to subtype CKD by disease severity are known to be imprecise, and are based on the degree of kidney damage that has already occurred rather than risk factors, particularly for early- vs. late-onset disease. We explore how the use of dynamic #biomarkers discovered via nontargeted approaches can provide new value in understanding the heterogeneous disease biology of CKD, to better predict disease progression and subtype patients by risk factors beyond #genetics: https://lnkd.in/gehzdWt4

We're #hiring a new Research Scientist III in San Diego, California. Apply today or share this post with your network.

Thank you to #GEN for covering our exciting collaboration with Rancho BioSciences! The expansion of our multi-omics database, which includes real-world data curated for discovery, will increase the breadth and depth of multidimensional insights we can deliver to accelerate drug development.

We're really enjoying the conversations here at #BiomarkersUS and thank everyone that joined Mo Jain, MD PhD for his talk! It's clear that the #biomarker field is rapidly evolving, with so many advancements even since the time of this conference last year. Many exciting applications for #multiomics data have already been discussed, for a diverse range of therapeutic development programs, and we look forward to continuing the conversations today. Visit us at Booth 13 or message Sapient via the Swapcard app to set a time to connect with our team! #BiomarkersOG #BiomarkersSeries Oxford Global

We're ready for Day 1 of #BiomarkersUS! Stop by Sapient's Booth 13 to meet our team including Sean Ramsey, KJ Banuk, Mo Jain, MD PhD, and Jonathan Usuka. Also don't miss Dr. Jain's scientific session at 12:00pm, where he will discuss how #biopharma companies are leveraging #multiomics data from early target identification through to clinical studies. (Track 2 meeting room) See you here! #BiomarkersOG Oxford Global

🚀 **Sapient partners with Rancho BioSciences to accelerate the next generation of its Human Biology Database** 🚀 Sapient is excited to announce its collaboration with Rancho BioSciences to expand and accelerate the development of our **Human Biology Database**. This next-gen infrastructure will enable rapid ingestion and homogenization of multi-omics and real-world data, allowing us to deliver even more robust insights for our clients in biomarker discovery and drug development. *“We believe strongly that integrated multi-omics data will play a critical role in the future of drug development, revealing how varied molecular interactions influence disease,”* said Tao Long, Co-Founder and Head of Data Science at Sapient. *“This partnership with Rancho BioSciences will create a pathway to efficiently add more types of omics data and increase the speed, versatility, and depth of our analyses.”* We are thrilled to work with Rancho BioSciences and leverage their expertise in life science data curation to support the future of data-driven insights for precision medicine. #BiomarkerDiscovery #MultiOmics #DataScience #DrugDevelopment #RealWorldData #LifeSciences #Sapient #RanchoBioSciences #PrecisionMedicine #OmicsData